Table of Contents
ISRN Pathology
Volume 2014, Article ID 124746, 8 pages
http://dx.doi.org/10.1155/2014/124746
Research Article

Zoledronic Acid Elicits Proinflammatory Cytokine Profile in Osteolytic Prostate Cancer Cells

1Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 11101, Taiwan
2Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei City 24205, Taiwan
3Central Laboratory, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 11101, Taiwan
4Department of Urology, Taipei Medical University, Taipei 11031, Taiwan

Received 24 January 2014; Accepted 12 March 2014; Published 23 April 2014

Academic Editors: A. Ozcan and Y. Wang

Copyright © 2014 Yi-Chia Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. P. Luckman, D. E. Hughes, F. P. Coxon, R. G. G. Russell, and M. J. Rogers, “Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras,” Journal of Bone and Mineral Research, vol. 13, no. 4, pp. 581–589, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. S. C. L. M. Cremers, G. Pillai, and S. E. Papapoulos, “Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis,” Clinical Pharmacokinetics, vol. 44, no. 6, pp. 551–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Morgan and A. Lipton, “Antitumor effects and anticancer applications of bisphosphonates,” Seminars in Oncology, vol. 37, supplement 2, pp. S30–S40, 2010. View at Google Scholar · View at Scopus
  4. I. R. Reid, G. D. Gamble, P. Mesenbrink, P. Lakatos, and D. M. Black, “Characterization of and risk factors for the acute-phase response after zoledronic acid,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4380–4387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Tanvetyanon and P. J. Stiff, “Management of the adverse effects associated with intravenous bisphosphonates,” Annals of Oncology, vol. 17, no. 6, pp. 897–907, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. S. Wilkinson, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin, “Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis,” Journal of the National Cancer Institute, vol. 99, no. 13, pp. 1016–1024, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Novince, B. B. Ward, and L. K. McCauley, “Osteonecrosis of the jaw: an update and review of recommendations,” Cells Tissues Organs, vol. 189, no. 1–4, pp. 275–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. L. Scheller, K. D. Hankenson, J. S. Reuben, and P. H. Krebsbach, “Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production,” Journal of Cellular Biochemistry, vol. 112, no. 11, pp. 3364–3372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Tsagozis, F. Eriksson, and P. Pisa, “Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages,” Cancer Immunology, Immunotherapy, vol. 57, no. 10, pp. 1451–1459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Giraudo, M. Inoue, and D. Hanahan, “An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis,” Journal of Clinical Investigation, vol. 114, no. 5, pp. 623–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C. Dumon, F. Journé, N. Kheddoumi, L. Lagneaux, and J. J. Body, “Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells,” European Urology, vol. 45, no. 4, pp. 521–528, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. Lin, Y. C. Lin, Y. H. Lin et al., “Zoledronic acid induces autophagic cell death in human prostate cancer cells,” Journal of Urology, vol. 185, no. 4, pp. 1490–1496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Gupta, M. Srivastava, N. Ahmad et al., “Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma,” Prostate, vol. 42, no. 1, pp. 73–78, 2000. View at Google Scholar
  14. R. Coleman, R. Cook, V. Hirsh, P. Major, and A. Lipton, “Zoledronic acid use in cancer patients,” Cancer, vol. 117, no. 1, pp. 11–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Saad, “Zoledronic acid: past, present and future roles in cancer treatment,” Future Oncology, vol. 1, no. 2, pp. 149–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Green, “Antitumor effects of bisphosphonates,” Cancer, vol. 97, supplement 3, pp. 840–847, 2003. View at Google Scholar · View at Scopus
  17. A. Bardia, E. A. Platz, S. Yegnasubramanian, A. M. de Marzo, and W. G. Nelson, “Anti-inflammatory drugs, antioxidants, and prostate cancer prevention,” Current Opinion in Pharmacology, vol. 9, no. 4, pp. 419–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Haverkamp, B. Charbonneau, and T. L. Ratliff, “Prostate inflammation and its potential impact on prostate cancer: a current review,” Journal of Cellular Biochemistry, vol. 103, no. 5, pp. 1344–1353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sutcliffe and E. A. Platz, “Inflammation in the etiology of prostate cancer: an epidemiologic perspective,” Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 3, pp. 242–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. de Marzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Shiirevnyamba, T. Takahashi, H. Shan et al., “Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts,” British Journal of Cancer, vol. 104, no. 3, pp. 505–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Morrissey, J. S. Lai, L. G. Brown et al., “The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells,” Prostate, vol. 70, no. 4, pp. 412–424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Tawara, J. T. Oxford, and C. L. Jorcyk, “Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies,” Cancer Management and Research, vol. 3, no. 1, pp. 177–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Costello, “Contemporary view of prostate cancer diagnosis and treatment,” Australian Family Physician, vol. 32, no. 6, pp. 396–398, 2003. View at Google Scholar · View at Scopus
  25. N. M. Corcoran and A. J. Costello, “Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?” BJU International, vol. 91, no. 6, pp. 545–553, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. F. R. Santer, K. Malinowska, Z. Culig, and I. T. Cavarretta, “Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 241–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ara and Y. A. Declerck, “Interleukin-6 in bone metastasis and cancer progression,” European Journal of Cancer, vol. 46, no. 7, pp. 1223–1231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Paule, S. Terry, L. Kheuang, P. Soyeux, F. Vacherot, and A. de Taille, “The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?” World Journal of Urology, vol. 25, no. 5, pp. 477–489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Culig, H. Steiner, G. Bartsch, and A. Hobisch, “Interleukin-6 regulation of prostate cancer cell growth,” Journal of Cellular Biochemistry, vol. 95, no. 3, pp. 497–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. T.-T. Hung, J. Chan, P. J. Russell, and C. A. Power, “Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model,” PLoS ONE, vol. 6, no. 5, Article ID e19389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Richardsen, R. D. Uglehus, J. Due, C. Busch, and L.-T. Busund, “COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and Ki67,” Cancer Epidemiology, vol. 34, no. 3, pp. 316–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. R. E. Harris, “Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung,” Inflammopharmacology, vol. 17, no. 2, pp. 55–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. A. Gallego, S. D. Prado, P. J. Fonseca, R. G. Campelo, J. C. Espinosa, and L. M. A. Aparicio, “Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer,” Clinical and Translational Oncology, vol. 9, no. 11, pp. 694–702, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Takahashi, H. Uehara, Y. Bando, and K. Izumi, “Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth,” Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2807–2816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. L. Neville-Webbe, M. Gnant, and R. E. Coleman, “Potential anticancer properties of bisphosphonates,” Seminars in Oncology, vol. 37, supplement 1, pp. S53–S65, 2010. View at Publisher · View at Google Scholar · View at Scopus